Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington's Disease (the "SIGNAL Trial") at Cambridge Healthtech Institute's 18th Annual PepTalk

January 17, 2019

ROCHESTER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces vice president of preclinical research, Elizabeth Evans, Ph.D., provided a podium presentation at the Cambridge Healthtech Institute's 18 th Annual PepTalk on the company's anti-SEMA4D research and data from its Phase 2 trial in Huntington's Disease.

"We are honored to again be invited to share our findings with the scientific community on the antibody blockade of the SEMA4D molecule, and its potential for treating neurodegenerative disease. We continue to be optimistic regarding the potential of our molecule, pepinemab, and look forward to providing further clinical updates," said Maurice Zauderer, Ph.D., CEO of Vaccinex.

Dr. Evans's presentation, "An Emerging Role for Glial Cells and Guidance Molecules in Neurodegeneration," outlines the pathogenic role that the SEMA4D protein plays in neurodegeneration and the company's experience with its monoclonal antibody, VX15 (pepinemab), in blocking the molecule. The CHI PepTalk was held January 14-15 at the Hilton San Diego Bayfront in San Diego, Calif.

About Vaccinex, Inc.

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in Rochester, New York.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. ("Vaccinex," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "potential," "advance," and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements may involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab (VX15), and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Securities and Exchange Commission ("SEC") and the other risks and uncertainties described in our prospectus for our initial public offering dated August 9, 2018, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended.

Investor Contact
Michael Rice
LifeSci Advisors, LLC
Phone: (646) 597-6979
E-mail: mrice@lifesciadvisors.com

Media Contact
Jules Abraham
JQA Partners, Inc.
Phone: (917) 885-7378
E-mail: jabraham@jqapartners.com

Vaccinex, Inc.